Karolinska Development AB (publ)

0P3C LN

0P3C LNKarolinska Development AB (publ)

FIGI: BBG00JHW1BF7

1.61

SEK

- -

-0.15EPS Dil.

-10.51P/E

434.05MMarket Cap

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Karolinska Development AB (publ)

0P3C:LN

()

Recent

price

1.61

P/E

ratio

-114.51

div

yld

- -

ROIC.AI

Legends:

Stock price

- -

Beta (1.0 Market)

% total return 09/23

Stock

S&P500

YTD

-13.28

- -

Capital Structure

USD

•

in mil. unless spec.

Dec'22

Mar'23

Jun'23

ST Debt

12,345

LT Borrowings

12,345

LT Finance Leases

12,345

Preferred Equity and Hybrid Capital

12,345

Shares Outstanding

12,345

Market Capitalization

12,345

Working Capital

USD

•

in mil. unless spec.

Dec'22

Mar'23

Jun'23

Total Current Assets

12,345

Cash, Cash Equivalents & STI

12,345

Accounts Receivable, Net

12,345

Inventories

12,345

Total Current Liabilities

12,345

Payables & Accruals

12,345

ST Debt

12,345

Deferred Revenue

12,345

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

12,345

Net Income, GAAP

12,345

Free Cash Flow

12,345

Total Cash Common Dividend

12,345

Total Equity

12,345

Quarterly Revenue

USD

•

in mil. unless spec.

Year

2021

12,345

2022

12,345

2023

12,345

- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

2021

12,345

2022

12,345

2023

12,345

- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

2021

12,345

2022

12,345

2023

12,345

- -

Business: Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.

Karolinska Development AB (publ)

0P3C LN

0P3C LNKarolinska Development AB (publ)

FIGI: BBG00JHW1BF7

Business: Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.

Karolinska Development AB (publ)

0P3C:LN

()

Recent

price

1.61

P/E

ratio

-114.51

div

yld

- -

ROIC.AI

Legends:

Stock price

- -

Beta (1.0 Market)

% total return 09/23

Stock

S&P500

YTD

-13.28

- -

-0.15EPS Dil.

-10.51P/E

434.05MMarket Cap

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

12,345

Net Income, GAAP

12,345

Free Cash Flow

12,345

Total Cash Common Dividend

12,345

Total Equity

12,345

Capital Structure

USD

•

in mil. unless spec.

Dec'22

Mar'23

Jun'23

ST Debt

12,345

LT Borrowings

12,345

LT Finance Leases

12,345

Preferred Equity and Hybrid Capital

12,345

Shares Outstanding

12,345

Market Capitalization

12,345

Working Capital

USD

•

in mil. unless spec.

Dec'22

Mar'23

Jun'23

Total Current Assets

12,345

Cash, Cash Equivalents & STI

12,345

Accounts Receivable, Net

12,345

Inventories

12,345

Total Current Liabilities

12,345

Payables & Accruals

12,345

ST Debt

12,345

Deferred Revenue

12,345

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

2021

12,345

2022

12,345

2023

12,345

- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

2021

12,345

2022

12,345

2023

12,345

- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

2021

12,345

2022

12,345

2023

12,345

- -

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

TTM

USD

- -

12,345

- -

12,345

- -

12,345

- -

12,345

- -

12,345

- -

12,345

- -

12,345

- -

12,345

- -

12,345

- -

12,345

- -

12,345

- -

12,345

- -

12,345

- -

12,345

- -

12,345

- -

12,345

- -

12,345

- -

12,345